PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)

被引：0

作者：

Harrison, C. ^{[1
]}

Szoke, A. ^{[2
]}

Suvorov, A. ^{[3
]}

Egyed, M. ^{[4
]}

Prasad, R. ^{[5
]}

Mayer, J. ^{[6
]}

Jakucs, J. ^{[7
]}

Elinder, A. ^{[8
]}

Recher, C. ^{[9
]}

te Boekhorst, P. A. ^{[10
]}

Knapper, S. ^{[11
]}

Somervaille, T. ^{[12
]}

Ciceri, F. ^{[13
]}

Quddus, F. ^{[14
]}

Straetmans, N. ^{[15
]}

Niederwieser, D. ^{[16
]}

Dean, J. P. ^{[17
]}

Granston, T.

Kiladjian, J. J. ^{[18
]}

Vannucchi, A. ^{[19
]}

Nangalia, J. ^{[20
]}

Mead, A. ^{[21
]}

Mesa, R. ^{[22
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, London, England

[2] Univ Szeged, Albert Szent Gyorgyi Clin Ctr, Szeged, Hungary

[3] Minist Hlth Udmurt Republ, Republican Clin Hosp 1, Izhevsk, Russia

[4] Kaposi Mor Teaching Hosp, Kaposvar, Hungary

[5] Royal Hobart Hosp, Hobart, Tas, Australia

[6] Univ Hosp Brno, Brno, Czech Republic

[7] Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary

[8] North Shore Hosp, Takapuna, New Zealand

[9] Inst Univ Canc Toulouse, Toulouse, France

[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

[11] Cardiff Univ, Cardiff, Wales

[12] Christie NHS Fdn Trust, Manchester, Lancs, England

[13] Ist Sci San Raffaele, I-20132 Milan, Italy

[14] Upstate Oncol Associates, Greenville, SC USA

[15] Ctr Hosp Jolimont Lobbes, Haine St Paul, Belgium

[16] Univ Klinikum Leipzig, Leipzig, Germany

[17] CTI BioPharma Corp, Seattle, WA USA

[18] Hop St Louis, Paris, France

[19] Univ Florence, Florence, Italy

[20] Univ Cambridge, Cambridge, England

[21] Univ Oxford, Oxford, England

[22] Mayo Clin, Scottsdale, AZ USA

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB314

引用

页码：103 / 103

页数：1

共 50 条

[1] Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Mesa, Ruben A.
Egyed, Miklos
Szoke, Anita
Suvorov, Aleksandr
Perkins, Andrew
Mayer, Jiri
Ganly, Peter
Jourdan, Eric
Schouten, Harry C.
Tosi, Patrizia
Farber, Charles Michael
Zachee, Pierre
Scheid, Christof
Dean, James P.
Cernohous, Paul
Nangalia, Jyoti
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Mead, Adam
Harrison, Claire N.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)
Mesa, Ruben A.
Egyed, Miklos
Szoke, Anita
Suvorov, Aleksandr
Perkins, Andrew
Mayer, Jiri
Ganly, Peter
Jourdan, Eric
Schouten, Harry C.
Tosi, Patrizia
Farber, Charles Michael
Zachee, Pierre
Scheid, Christof
Dean, James P.
Cernohous, Paul
Nangalia, Jyoti
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Mead, Adam
Harrison, Claire N.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[3] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Barosi, G.
Linardi, C.
Ben Yehuda, D.
Henrique Daumas Gabriel, A.
Perez, J.
Modi, A.
Khan, M.
Zweegman, S.
Raymakers, R.
Vianelli, N.
Pakstyte, S.
Willenbacher, W.
Gisslinger, H.
HAEMATOLOGICA, 2012, 97 : 321 - 321
[4] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Vargas, P.
Karpovitch, X.
Alvarado, M.
Ovilla, R.
Agreda, G.
Guzman, P.
Solis, J.
Kassack, J.
Silva, S.
Zavala, S.
Morales, J.
Herrera, A.
Reynoso, E.
Rodriguez, M.
Ruiz, G.
Sobrevilla, P.
Garcia, M.
Aguilar, C.
Morales, R.
Barrera, E.
Osuna, A.
Carrillo, R.
Silos, G.
Vega, A.
Cuin, S.
Mora, M.
Best, C.
Murillo, E.
Loarca, L.
Perez, O.
Salazar, J.
Baez, E.
Montemayor, J.
Barrera, D.
Garcia, J.
Peraza, L.
Baltazar, S.
Iniguez, L.
Oseguera, R.
Nacho, K.
Romero, T.
HAEMATOLOGICA, 2013, 98 : 765 - 766
[5] A PHASE 1B, DOSE-FINDING STUDY OF RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS (MF), POST-POLYCYTHEMIA VERA MF (PPV-MF), OR POST-ESSENTIAL (PET-MF) THROMBOCYTHEMIA MF
Harrison, N.
Kiladjian, J. J.
Passamonti, F.
Vannucchi, A.
Gadbaw, B.
Acharyya, S.
Woo, M.
Liu, T.
Sirulnik, A.
Conneally, E.
Giles, F.
Kindler, T.
Heidel, F.
Ribrag, V.
HAEMATOLOGICA, 2012, 97 : 146 - 146
[6] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
Barosi, Giovanni
Agarwal, Mohan
Zweegman, Sonja
Willenbacher, Wolfgang
Pakstyte, Sima
Raymakers, Reinier
Cantoni, Nathan
Modi, Ankur
Khan, Mahmudul
Perez, Jose Ricardo
Hasselbalch, Hans
Vargas Viveros, Jose Pablo
Linardi, Camila C. G.
Gisslinger, Heinz
Daumas Gabriel, Adelmo Henrique
Palandri, Francesca
Lavie, David
Harrison, Claire N.
BLOOD, 2012, 120 (21)
[7] Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
Harrison, C. N.
Kiladjian, J.
Al-Ali, H. K.
Gisslinger, H.
Waltzman, R. J.
Stalbovskaya, V.
McQuitty, M.
Hunter, D. S.
Levy, R. S.
Cervantes, F.
Vannucchi, A. M.
Barbui, T.
Barosi, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
McMullin, Mary Frances
Harrison, Claire N.
Niederwieser, Dietger
Demuynck, Hilde
Jakel, Nadja
Sirulnik, Andres
McQuity, Mari
Stalbovskaya, Viktoriya
Recher, Christian
Theunissen, Koen
Gisslinger, Heinz
Kiladjian, Jean-Jacques
Al-Ali, Haifa-Kathrin
BLOOD, 2012, 120 (21)
[9] Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF)
Harrison, C. N.
Kiladjian, J.
Al-Ali, H. K.
Gisslinger, H.
Waltzman, R. J.
Stalbovskaya, V.
McQuitty, M.
Hunter, D. S.
Levy, R. S.
Cervantes, F.
Vannucchi, A. M.
Barbui, T.
Barosi, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
[10] Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan
Hou, Hsin-An
Lin, Chien-Chin
Kuo, Ming-Chung
Lin, Shyuann-Yuh
Gau, Jyh-Pyng
Wang, Ming-Chung
Chang, Ming-Chih
Chen, Tsung-Chih
Yeh, Su-Peng
Chen, Yeu-Chin
Huang, Cih-En
Chen, Chieh-Wen
Lee, Yee-Ming
Ku, Fan-Chen
Shih, Lee-Yung
BLOOD, 2019, 134

← 1 2 3 4 5 →